News
NCNA
4.000
+4.99%
0.190
Weekly Report: what happened at NCNA last week (0415-0419)?
Weekly Report · 6d ago
NuCana Executes Reverse ADS Split to Boost Liquidity
TipRanks · 04/16 12:57
NuCana Announces Completion Of 1-For-25 ADS Ratio Change
NuCana plc will change the ratio of its American Depositary Shares to its ordinary shares. The change in the ADS Ratio became effective on April 16, 2024. The Company's ADSs continue to be traded on the Nasdaq Capital Market under the ticker symbol "NCNA"
Benzinga · 04/16 12:14
Weekly Report: what happened at NCNA last week (0408-0412)?
Weekly Report · 04/15 09:04
NuCana Reveals NUC-7738’s Anti-Cancer Potential
TipRanks · 04/09 21:29
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
Barchart · 04/09 15:30
Weekly Report: what happened at NCNA last week (0401-0405)?
Weekly Report · 04/08 09:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. AN2 Therapeutics (NASdaq:ANTX) shares rose by 6.76%. Candel Therapeutic stock moved upwards by 4.99% during the day. Losers AcordaTherapeutics and WAVE Life Sciences lost 8.9% and 7.1% respectively.
Benzinga · 04/04 20:31
Weekly Report: what happened at NCNA last week (0325-0329)?
Weekly Report · 04/01 09:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Avalo Therapeutics stock rose 289.1% to $18.48 during Friday's pre-market session. Xilio Therapeutic (XLO) shares moved upwards by 205.16% during the session. Biodexa Pharmaceuticals (BDRX) shares also moved upwards. Losers NuCana (NCNA) and Yield10 Bioscience (YTEN) fell in the pre- market session.
Benzinga · 03/29 12:06
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 03/28 18:08
12 Health Care Stocks Moving In Thursday's Intraday Session
Avalo Therapeutics (NASDAQ:AVTX) stock rose 363.1% to $22.0 during Thursday's regular session. The company's market cap stands at $17.6 million. Biodexa Pharmaceuticals and Ontrak stock increased by 71.82% and 37.66% respectively. Q4 earnings came out today.
Benzinga · 03/28 16:31
Why NuCana (NCNA) Shares Are Trading Lower
NuCana plc shares are trading lower by 15.2% to $0.26. Company says it intends to adjust ratio of its American Depository Shares to its ordinary shares from 1:1 to 1:25. The change is expected to be effective around April 16.
Benzinga · 03/28 15:41
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, B Riley, Xilio Therapeutics
Wall Street's main stock indexes set to open flat on Thursday in thin trading ahead of Easter break. Dow e-minis up 0.11%, S&P 500 and Nasdaq 100 down 0.02%. Top three NYSE percentage gainers premarket: Cazoo Group, Xilio Therapeutics. Gold miners rise on U.S. Interest rate cut bets. B Riley Financial up 6.7% in premarket.
Reuters · 03/28 13:18
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company's shares jumped 9.4% to $324.99 in pre-market trading. Avalo Therapeutics, Inc. Gained 256.6% on Wednesday.
Benzinga · 03/28 12:21
Truist Financial Sticks to Its Buy Rating for Nucana (NCNA)
Robyn Karnauskas from Truist Financial maintained a Buy rating on Nucana. The company’s shares closed yesterday at $0.31. The firm has a one-year high of $1.00 and a low of $.23. The analyst consensus rating suggests a Moderate Buy.
TipRanks · 03/28 12:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. Xilio Therapeutic (XLO) stock moved upwards by 223.94% during the session. Akanda (AKAN) shares increased by 27.1% and INVO Bioscience (INVO) stock increased by 16.36%. NuCana (NCNA) stock declined by 19.8% in the pre- market.
Benzinga · 03/28 12:06
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday. Avalo Therapeutics stock is rocketing more than 268% after announcing a $185 million private placement. Moving stocks this morning are public debuts, earnings reports and more. Ten of the biggest pre-market stocks moving shares this morning.
Investorplace · 03/28 11:43
NuCana plc Announces Reverse ADS Split
TipRanks · 03/27 21:27
NuCana announces plan to implement ADS ratio change
Healthcare NuCana announces plan to implement ADS ratio change. Shares of NCNA fell 5.4% in extended trading. The change in the ADS Ratio is expected to become effective on or about April 16. NCNA plans to change the ratio of its American Depository Shares to its ordinary shares.
Seeking Alpha · 03/27 20:37
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.